Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced RCC.
figure
posted on 2022-06-27, 07:34 authored by Jianxin Pang, Peihao Wu, Yanqing Jiang, Junyan Wu, Kaifeng Qiu, Ruizhe LiuFigure S1. Kaplan–Meier curves and modelled curves.
History
Usage metrics
Categories
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC